Study Type
Interventional - Drug
completed
Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI).
We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI.
The objective of the PCI-CURE study was to determine if, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after a patient undergoes percutaneous coronary intervention (PCI) is superior to a strategy of no pretreatment and short-term therapy for only four weeks after PCI.
Patients with non-ST-elevation acute coronary syndrome undergoing PCI in our CURE study were randomly assigned double-blind treatment with clopidogrel or placebo.
Primary endpoint:
A composite of cardiovascular death, myocardial infarction, or urgent target-vessel revascularisation within 30 days of PCI.
We concluded that in patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo.
Study Design
Randomized double-blind
NO. of Countries
28
NO. of Sites
482
NO. of Participants
2658
Study Period
1998 - 2001
Sponsor
Sanofi
Shamir Mehta
Senior Scientist
Shamir Mehta
Senior Scientist
Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI. He holds the Douglas A. Holder Endowed Chair and is a Professor of Medicine at McMaster University. Mehta directs the Royal College fellowship in interventional cardiology and leads the mitral and tricuspid valve transcatheter edge-to-edge repair programs at Hamilton Health Sciences and McMaster University. He completed his medical education and postgraduate training at the University of Toronto, followed by a research fellowship at McMaster University, supported by a Canadian Institutes of Health Research New Investigator Award.
At PHRI, he leads landmark clinical trials that evaluate revascularization strategies and new pharmacologic interventions for patients with acute coronary syndromes. Mehta is the Principal Investigator of the COMPLETE-2 trial, a 5,100-patient multinational study comparing physiology-guided and angiography-guided PCI strategies for treating non-culprit lesions in patients with acute coronary syndrome and multivessel coronary artery disease. This trial includes a large-scale intracoronary imaging study using optical coherence tomography to predict cardiovascular events. He also serves on the executive committee of the Librexia ACS trial, which is testing a novel Factor XIa inhibitor in acute coronary syndromes, and he is a steering committee member of OCEAN(a), focusing on targeted lowering of lipoprotein(a) with a novel small interfering RNA after acute coronary syndrome or PCI.
Dr. Mehta has published hundreds of research articles and has secured millions of dollars in peer-reviewed research grants from CIHR and industry. In 2022, he received the Canadian Cardiovascular Society’s Research Achievement Award. In 2024, he received the Canadian Association of Interventional Cardiology Outstanding Achievement Award.
completed
OASIS 4 CURE
Interventional Cardiology
OASIS 4, a phase III, double-blind, parallel group randomized clinical trial, evaluated the efficacy and...
